

Defects in succinate dehydrogenase in gastrointestinal
and *PDGFRA* mutations

Proceedings of the National Academy of Sciences of the United States of America
108, 314-318

DOI: [10.1073/pnas.1009199108](https://doi.org/10.1073/pnas.1009199108)

Citation Report

#	ARTICLE	IF	CITATIONS
1	SDHA Loss-of-Function Mutations in KIT-PDGFR α Wild-Type Gastrointestinal Stromal Tumors Identified by Massively Parallel Sequencing. <i>Journal of the National Cancer Institute</i> , 2011, 103, 983-987.	3.0	137
3	Gastrointestinal Stromal Tumor Surgery and Adjuvant Therapy. <i>Surgical Clinics of North America</i> , 2011, 91, 1079-1087.	0.5	27
4	Genetic Interactions in Cancer Progression and Treatment. <i>Cell</i> , 2011, 145, 30-38.	13.5	380
5	Molecular Pathology of Gastrointestinal Stromal Tumors and Implications for Treatment and Prognosis. <i>Current Problems in Cancer</i> , 2011, 35, 245-254.	1.0	3
6	Gastrointestinal stromal tumours in children and young adults: A clinicopathologic series with long-term follow-up from the database of the Cooperative Weichteilsarkom Studiengruppe (CWS). <i>European Journal of Cancer</i> , 2011, 47, 1692-1698.	1.3	26
7	In Search of Targeted Therapies for Childhood Cancer. <i>Frontiers in Oncology</i> , 2011, 1, 18.	1.3	11
9	Succinate Dehydrogenase-Deficient GISTs. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1712-1721.	2.1	319
10	Renal Tumors Associated With Germline SDHB Mutation Show Distinctive Morphology. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1578-1585.	2.1	184
11	A Distinct Pediatric-type Gastrointestinal Stromal Tumor in Adults. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1750-1752.	2.1	40
12	“Pediatric-Type” Gastrointestinal Stromal Tumors Are SDHB Negative (“Type 2”) GISTs. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1245-1247.	2.1	46
13	Gastrointestinal stromal tumours: origin and molecular oncology. <i>Nature Reviews Cancer</i> , 2011, 11, 865-878.	12.8	711
14	Mitochondrial respiratory chain complexes: apoptosis sensors mutated in cancer?. <i>Oncogene</i> , 2011, 30, 3985-4003.	2.6	99
15	SDH mutations in cancer. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2011, 1807, 1432-1443.	0.5	327
17	Challenging issues in pediatric oncology. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 540-549.	12.5	180
18	Gastrointestinal Stromal Tumor: Advances in Diagnosis and Management. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 1298-1310.	1.2	94
19	Use of Colony-Stimulating Factors With Chemotherapy: Opportunities for Cost Savings and Improved Outcomes. <i>Journal of the National Cancer Institute</i> , 2011, 103, 979-982.	3.0	85
20	No Child Left Behind in SDHB Testing for Paragangliomas and Pheochromocytomas. <i>Journal of Clinical Oncology</i> , 2011, 29, 4070-4072.	0.8	14
21	Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors. <i>Clinical Medicine Insights: Oncology</i> , 2011, 5, CMO.S4259.	0.6	16

#	ARTICLE	IF	CITATIONS
22	Metastatic Pheochromocytoma/Paraganglioma Related to Primary Tumor Development in Childhood or Adolescence: Significant Link to <i>SDHB</i> Mutations. <i>Journal of Clinical Oncology</i> , 2011, 29, 4137-4142.	0.8	170
23	Gastrointestinal Stromal Tumors. <i>Current Topics in Microbiology and Immunology</i> , 2011, 355, 41-57.	0.7	5
24	Soft Tissue Tumors of Uncertain Origin. <i>Pediatric and Developmental Pathology</i> , 2012, 15, 267-305.	0.5	17
25	Succinate Dehydrogenase B Subunit Immunohistochemical Expression Predicts Aggressiveness in Well Differentiated Neuroendocrine Tumors of the Ileum. <i>Cancers</i> , 2012, 4, 808-820.	1.7	6
26	Pathology of Gastrointestinal Stromal Tumors. <i>Clinical Medicine Insights Pathology</i> , 2012, 5, CPath.S9689.	0.6	42
27	A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.6	44
28	Predictors of Response to Targeted Therapies for Gastrointestinal Stromal Tumors. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 483-489.	1.2	39
29	GENETICS IN ENDOCRINOLOGY: The genetics of pheochromocytoma: using clinical features to guide genetic testing. <i>European Journal of Endocrinology</i> , 2012, 166, 151-158.	1.9	98
30	Treatment Guidelines for Gastrointestinal Stromal Tumors in Children and Young Adults. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, S69-S72.	0.3	36
31	Intracranial Metastasis From Pediatric GI Stromal Tumor. <i>Journal of Clinical Oncology</i> , 2012, 30, e122-e125.	0.8	14
32	Therapeutic Kinase Inhibitors. <i>Current Topics in Microbiology and Immunology</i> , 2012, , .	0.7	1
35	Succinate dehydrogenase-deficient GISTs are characterized by IGF1R overexpression. <i>Modern Pathology</i> , 2012, 25, 1307-1313.	2.9	46
36	KIT Mutations and Sequence Changes in Genes Encoding SDH Complex Possibly Need Not be Mutually Exclusive in Gastrointestinal Stromal Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2012, 20, 523-524.	0.6	5
37	Recessive germline <i>SDHA</i> and <i>SDHB</i> mutations causing leukodystrophy and isolated mitochondrial complex II deficiency. <i>Journal of Medical Genetics</i> , 2012, 49, 569-577.	1.5	100
38	Adolescent and Young Adult Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1112-1150.	2.3	173
39	Multiplex mutation screening by mass spectrometry in gastrointestinal stromal tumours. <i>Pathology</i> , 2012, 44, 460-464.	0.3	4
42	Soft Tissue Sarcoma, Version 2.2012. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 951-960.	2.3	117
43	Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. <i>Pathology</i> , 2012, 44, 285-292.	0.3	168

#	ARTICLE	IF	CITATIONS
44	Pediatric gastrointestinal stromal tumor. <i>Seminars in Pediatric Surgery</i> , 2012, 21, 31-43.	0.5	40
45	New Strategies in Sarcoma Therapy: Linking Biology and Novel Agents. <i>Clinical Cancer Research</i> , 2012, 18, 5837-5844.	3.2	9
46	Targeting Cancer Metabolism. <i>Clinical Cancer Research</i> , 2012, 18, 5537-5545.	3.2	125
47	Pericentric and centromeric transcription: a perfect balance required. <i>Chromosome Research</i> , 2012, 20, 535-546.	1.0	105
48	Characterization of <i>TALE</i> genes expression during the first lineage segregation in mammalian embryos. <i>Developmental Dynamics</i> , 2012, 241, 1827-1839.	0.8	13
50	Evolutionary history of linked D4Z4 and Beta satellite clusters at the FSHD locus (4q35). <i>Genomics</i> , 2012, 100, 289-296.	1.3	5
51	Succinate Dehydrogenase Kidney Cancer: An Aggressive Example of the Warburg Effect in Cancer. <i>Journal of Urology</i> , 2012, 188, 2063-2071.	0.2	211
52	Anti-tumor effects of the Notch pathway in gastrointestinal stromal tumors. <i>Carcinogenesis</i> , 2012, 33, 1674-1683.	1.3	18
53	SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors. <i>BMC Cancer</i> , 2012, 12, 408.	1.1	54
54	Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry. <i>BMC Cancer</i> , 2012, 12, 90.	1.1	41
55	Recent advances and novel agents for gastrointestinal stromal tumor (GIST). <i>Journal of Hematology and Oncology</i> , 2012, 5, 21.	6.9	30
56	Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications. <i>Clinical Sarcoma Research</i> , 2012, 2, 16.	2.3	49
57	Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 732-739.	1.5	93
59	The Management of Gastrointestinal Stromal Tumors: A Model for Targeted and Multidisciplinary Therapy of Malignancy. <i>Annual Review of Medicine</i> , 2012, 63, 247-258.	5.0	119
60	Carney Stratakis Syndrome in a Patient with SDHD Mutation. <i>Endocrine Pathology</i> , 2012, 23, 181-186.	5.2	6
61	Updates on the Management of Gastrointestinal Stromal Tumors. <i>Surgical Oncology Clinics of North America</i> , 2012, 21, 301-316.	0.6	47
63	Reduction of Prep1 Levels Affects Differentiation of Normal and Malignant B Cells and Accelerates Myc Driven Lymphomagenesis. <i>PLoS ONE</i> , 2012, 7, e48353.	1.1	9
64	Identification, Management, and Evaluation of Children with Cancer-Predisposition Syndromes. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 576-584.	1.8	24

#	ARTICLE	IF	CITATIONS
65	Gastrointestinal stromal tumors (GISTs): role of CD 117 and PDGFRA Golgi-like staining pattern in the recognition of mutational status. <i>Revista Espanola De Enfermedades Digestivas</i> , 2012, 104, 128-133.	0.1	5
66	A novel germline SDHB mutation in a gastrointestinal stromal tumor patient without bona fide features of the Carney-Stratakis dyad. <i>Familial Cancer</i> , 2012, 11, 189-194.	0.9	19
68	Diagnostic Tests and Biomarkers for Pheochromocytoma and Extra-adrenal Paraganglioma: From Routine Laboratory Methods to Disease Stratification. <i>Endocrine Pathology</i> , 2012, 23, 4-14.	5.2	95
69	Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study. <i>Histopathology</i> , 2012, 61, 801-809.	1.6	87
70	Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib. <i>Annals of Surgical Oncology</i> , 2012, 19, 1551-1559.	0.7	57
71	Cancer heterogeneity—a multifaceted view. <i>EMBO Reports</i> , 2013, 14, 686-695.	2.0	208
72	Management of Soft Tissue Sarcoma. , 2013, , .		38
73	Molecular alterations and expression of succinate dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal stromal tumors. <i>European Journal of Human Genetics</i> , 2013, 21, 503-510.	1.4	15
74	Extended Adjuvant Therapy with Imatinib in Patients with Gastrointestinal Stromal Tumors. <i>Molecular Diagnosis and Therapy</i> , 2013, 17, 9-19.	1.6	11
75	Epigenetics in Gastrointestinal Stromal Tumors: Clinical Implications and Potential Therapeutic Perspectives. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3094-3102.	1.1	9
76	Physiological consequences of complex II inhibition for aging, disease, and the mKATP channel. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2013, 1827, 598-611.	0.5	70
77	Succinate dehydrogenase expression in breast cancer. <i>SpringerPlus</i> , 2013, 2, 299.	1.2	39
78	MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours. <i>British Journal of Cancer</i> , 2013, 109, 1625-1635.	2.9	73
79	Gastrointestinal Stromal Tumors. <i>Gastroenterology Clinics of North America</i> , 2013, 42, 399-415.	1.0	189
80	Contributions of molecular analysis to the diagnosis and treatment of gastrointestinal neoplasms. <i>Seminars in Diagnostic Pathology</i> , 2013, 30, 329-361.	1.0	13
81	Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors. <i>Cancer Research</i> , 2013, 73, 3499-3510.	0.4	277
82	cAMP/PKA signaling defects in tumors: Genetics and tissue-specific pluripotential cell-derived lesions in human and mouse. <i>Molecular and Cellular Endocrinology</i> , 2013, 371, 208-220.	1.6	34
83	Newly Available Antibodies With Practical Applications in Surgical Pathology. <i>International Journal of Surgical Pathology</i> , 2013, 21, 553-572.	0.4	18

#	ARTICLE	IF	CITATIONS
84	Analysis of the DNA-Binding Profile and Function of TALE Homeoproteins Reveals Their Specialization and Specific Interactions with Hox Genes/Proteins. <i>Cell Reports</i> , 2013, 3, 1321-1333.	2.9	125
85	The role of complex II in disease. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2013, 1827, 543-551.	0.5	111
86	Gastrointestinal Stromal Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 871-888.	0.9	46
87	Respiratory chain complex II as general sensor for apoptosis. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2013, 1827, 565-572.	0.5	66
88	Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 214-224.	1.5	63
89	Paragangliomas: Update on differential diagnostic considerations, composite tumors, and recent genetic developments. <i>Seminars in Diagnostic Pathology</i> , 2013, 30, 207-223.	1.0	40
90	Targeted Therapy for Cancer. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 805-821.	0.6	12
91	The emerging role of mutational analysis in the management of gastrointestinal stromal tumour. <i>Diagnostic Histopathology</i> , 2013, 19, 198-202.	0.2	0
92	Mitochondrial complex II, a novel target for anti-cancer agents. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2013, 1827, 552-564.	0.5	87
93	SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors. <i>Modern Pathology</i> , 2013, 26, 456-463.	2.9	91
94	Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. <i>Modern Pathology</i> , 2013, 26, 289-294.	2.9	134
95	Expression of IGF-1 receptor in KIT/PDGFR- \pm wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction. <i>Future Oncology</i> , 2013, 9, 121-126.	1.1	30
96	SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma. <i>Cancer Cell</i> , 2013, 23, 739-752.	7.7	606
97	Succinate dehydrogenase deficiency is associated with decreased 5-hydroxymethylcytosine production in gastrointestinal stromal tumors: implications for mechanisms of tumorigenesis. <i>Modern Pathology</i> , 2013, 26, 1492-1497.	2.9	65
98	Novel Pathways and Molecular Targets for the Treatment of Sarcoma. <i>Current Oncology Reports</i> , 2013, 15, 378-385.	1.8	28
99	Gastrointestinal stromal tumours: pathology and differential diagnosis. <i>Diagnostic Histopathology</i> , 2013, 19, 211-219.	0.2	1
100	Gastrointestinal stromal tumour. <i>Lancet, The</i> , 2013, 382, 973-983.	6.3	518
101	Novel Hereditary Forms of Pheochromocytomas and Paragangliomas. <i>Frontiers of Hormone Research</i> , 2013, 41, 79-91.	1.0	13

#	ARTICLE	IF	CITATIONS
102	GISTogram: a graphic presentation of the growing GIST complexity. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 463, 481-487.	1.4	26
103	Genome-wide analyses of sarcoma: implications for future treatment options. <i>Future Oncology</i> , 2013, 9, 307-310.	1.1	0
104	Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy. <i>Pharmacogenomics</i> , 2013, 14, 941-956.	0.6	28
106	Means, Motive, and Opportunity: SDH Mutations Are Suspects in Pituitary Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2274-2276.	1.8	7
107	Familial SDHA Mutation Associated With Pituitary Adenoma and Pheochromocytoma/Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1103-E1108.	1.8	102
108	Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients. <i>Carcinogenesis</i> , 2013, 34, 2767-2773.	1.3	40
109	Leiomyoma arising within a mature cystic teratoma. <i>Pathology</i> , 2013, 45, 691-693.	0.3	2
110	The tubal fimbria: the old broom sweeps into prominence. <i>Pathology</i> , 2013, 45, 706-708.	0.3	0
111	High grade transformation in a case of adenoid cystic carcinoma associated with Epstein-Barr virus expression. <i>Pathology</i> , 2013, 45, 693-695.	0.3	6
112	Germline SDHC mutation presenting as recurrent SDH deficient GIST and renal carcinoma. <i>Pathology</i> , 2013, 45, 689-691.	0.3	48
113	Hydrops fetalis, hepatic centrilobular necrosis, and hypoxic-ischaemic encephalopathy in a fetus with premature closure of foramen ovale. <i>Pathology</i> , 2013, 45, 708-710.	0.3	1
114	Pyloric gland type intraductal tubular adenoma of the liver. <i>Pathology</i> , 2013, 45, 710-713.	0.3	0
115	KIT gene mutation analysis in solid tumours: biology, clinical applications and trends in diagnostic reporting. <i>Pathology</i> , 2013, 45, 127-137.	0.3	11
116	Diffuse large B-cell lymphoma/follicular lymphoma arising in a background of IgG4-related pachymeningitis. <i>Pathology</i> , 2013, 45, 696-698.	0.3	7
117	CRTC3-MAML2 fusion transcript in a bronchial mucoepidermoid carcinoma. <i>Pathology</i> , 2013, 45, 698-701.	0.3	3
118	A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas. <i>Clinical Cancer Research</i> , 2013, 19, 6020-6029.	3.2	80
119	Molecular and Therapeutic Advances in the Diagnosis and Management of Malignant Pheochromocytomas and Paragangliomas. <i>Oncologist</i> , 2013, 18, 391-407.	1.9	41
120	Succinate Dehydrogenase Mutation Underlies Global Epigenomic Divergence in Gastrointestinal Stromal Tumor. <i>Cancer Discovery</i> , 2013, 3, 648-657.	7.7	288

#	ARTICLE	IF	CITATIONS
121	Mixed dendritic cell tumours with follicular-fibroblastic dendritic cell features of lymph node. <i>Pathology</i> , 2013, 45, 704-706.	0.3	0
122	Prominent angiotropism in a small atypical spitzoid dysplastic melanocytic naevus: what is its significance?. <i>Pathology</i> , 2013, 45, 701-703.	0.3	2
123	Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors. <i>Frontiers in Oncology</i> , 2013, 3, 117.	1.3	44
124	An overview on molecular biology of KIT/PDGFR α wild type (WT) gastrointestinal stromal tumours (GIST). <i>Journal of Medical Genetics</i> , 2013, 50, 653-661.	1.5	78
125	Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFR α . <i>Cancer Medicine</i> , 2013, 2, 21-31.	1.3	26
126	A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del). <i>Modern Pathology</i> , 2013, 26, 1004-1012.	2.9	51
127	Immunohistochemical Loss of Succinate Dehydrogenase Subunit A (SDHA) in Gastrointestinal Stromal Tumors (GISTs) Signals SDHA Germline Mutation. <i>American Journal of Surgical Pathology</i> , 2013, 37, 234-240.	2.1	178
128	A Novel Germline KIT Mutation (p.L576P) in a Family Presenting With Juvenile Onset of Multiple Gastrointestinal Stromal Tumors, Skin Hyperpigmentations, and Esophageal Stenosis. <i>American Journal of Surgical Pathology</i> , 2013, 37, 898-905.	2.1	40
129	Expression of the Receptor for Type I Insulin-like Growth Factor (IGF1R) in Gastrointestinal Stromal Tumors. <i>American Journal of Surgical Pathology</i> , 2013, 37, 114-119.	2.1	69
130	Loss of SDHA Expression Identifies SDHA Mutations in Succinate Dehydrogenase-deficient Gastrointestinal Stromal Tumors. <i>American Journal of Surgical Pathology</i> , 2013, 37, 226-233.	2.1	119
131	Post-Transcriptional Dysregulation by miRNAs Is Implicated in the Pathogenesis of Gastrointestinal Stromal Tumor [GIST]. <i>PLoS ONE</i> , 2013, 8, e64102.	1.1	33
132	Membrane-To-Nucleus Signaling Links Insulin-Like Growth Factor-1- and Stem Cell Factor-Activated Pathways. <i>PLoS ONE</i> , 2013, 8, e76822.	1.1	14
133	GSTT1 Copy Number Gain and ZNF Overexpression Are Predictors of Poor Response to Imatinib in Gastrointestinal Stromal Tumors. <i>PLoS ONE</i> , 2013, 8, e77219.	1.1	13
134	Connecting Molecular Pathways to Hereditary Cancer Risk Syndromes. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 81-90.	1.8	14
135	The Deficiency of Tumor Suppressor Prep1 Accelerates the Onset of Meis1- Hoxa9 Leukemogenesis. <i>PLoS ONE</i> , 2014, 9, e96711.	1.1	8
136	Prep1 (pKnox1) Regulates Mouse Embryonic HSC Cycling and Self-Renewal Affecting the Stat1-Sca1 IFN-Dependent Pathway. <i>PLoS ONE</i> , 2014, 9, e107916.	1.1	9
137	Gastrointestinal Stromal Tumor – An Evolving Concept. <i>Frontiers in Medicine</i> , 2014, 1, 43.	1.2	15
138	Neoadjuvant and Adjuvant Therapy for Gastrointestinal Tumors. , 2014, 04, .		0

#	ARTICLE	IF	CITATIONS
139	18. Iron-sulfur proteins and human diseases. , 2014, , 455-512.		0
140	Novel Treatment Targets in Sarcoma: More Than Just the GIST. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e488-e495.	1.8	7
141	The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations. Endocrine, 2014, 47, 401-408.	1.1	41
142	Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors. Expert Opinion on Pharmacotherapy, 2014, 15, 1979-1989.	0.9	41
143	Prep1 and Meis1 competition for Pbx1 binding regulates protein stability and tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E896-905.	3.3	47
144	Integrated genomic study of quadruple-WT GIST (KIT/PDGFR/SDH/RAS pathway wild-type GIST). BMC Cancer, 2014, 14, 685.	1.1	70
145	Krebs Cycle Metabolite Profiling for Identification and Stratification of Pheochromocytomas/Paragangliomas due to Succinate Dehydrogenase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3903-3911.	1.8	111
146	Successes and Limitations of Targeted Cancer Therapy in Gastrointestinal Stromal Tumors. Progress in Tumor Research, 2014, 41, 51-61.	0.1	13
147	Managing GIST in the imatinib era: optimization of adjuvant therapy. Expert Review of Anticancer Therapy, 2014, 14, 1445-1459.	1.1	9
148	The LYR Factors SDHAF1 and SDHAF3 Mediate Maturation of the Iron-Sulfur Subunit of Succinate Dehydrogenase. Cell Metabolism, 2014, 20, 253-266.	7.2	96
149	Recent advances in the treatment of gastrointestinal stromal tumors. Therapeutic Advances in Medical Oncology, 2014, 6, 115-127.	1.4	60
150	Counseling patients with succinate dehydrogenase subunit defects: genetics, preventive guidelines, and dealing with uncertainty. Journal of Pediatric Endocrinology and Metabolism, 2014, 27, 837-44.	0.4	12
151	MDCT features of succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumours. British Journal of Radiology, 2014, 87, 20140476.	1.0	15
152	Surgical management of localized soft tissue tumors. Cancer, 2014, 120, 2638-2648.	2.0	40
153	Powerhouse down: Complex II dissociation in the respiratory chain. Mitochondrion, 2014, 19, 20-28.	1.6	37
154	Succinate Dehydrogenase Deficiency Is Rare in Pituitary Adenomas. American Journal of Surgical Pathology, 2014, 38, 560-566.	2.1	71
155	Succinate Dehydrogenase (SDH)-deficient Renal Carcinoma. American Journal of Surgical Pathology, 2014, 38, 1588-1602.	2.1	282
156	Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor. , 2014, 19, 74-77.		0

#	ARTICLE	IF	CITATIONS
157	Phenotypic Variability and Risk of Malignancy in <i>SDHC</i> -Linked Paragangliomas: Lessons From Three Unrelated Cases With an Identical Germline Mutation (p.Arg133*). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E489-E496.	1.8	23
158	Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours. <i>Endocrine-Related Cancer</i> , 2014, 21, 415-426.	1.6	34
159	Simultaneous <i>KIT</i> mutation and succinate dehydrogenase (<i>SDH</i>) deficiency in a patient with a gastrointestinal stromal tumour and Carney-Stratakis syndrome: a case report. <i>Histopathology</i> , 2014, 65, 712-717.	1.6	7
160	Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program. <i>Clinical Sarcoma Research</i> , 2014, 4, 17.	2.3	16
161	Mitochondrial Complex II in Cancer. , 2014, , 81-104.		0
162	A bittersweet symphony. <i>Endocrine-Related Cancer</i> , 2014, 21, C7-C9.	1.6	0
163	Mapping of Succinate Dehydrogenase Losses in 2258 Epithelial Neoplasms. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014, 22, 31-36.	0.6	38
164	Rhabdoid morphology in gastrointestinal stromal tumours (<i>GIST</i> s) is associated with <i>PDGFRA</i> mutations but does not imply aggressive behaviour. <i>Histopathology</i> , 2014, 64, 421-430.	1.6	8
165	Rare insights into cancer biology. <i>Oncogene</i> , 2014, 33, 2547-2556.	2.6	74
166	Diagnosis and management of pheochromocytoma. <i>Current Problems in Surgery</i> , 2014, 51, 151-187.	0.6	47
167	Wild-type <i>GIST</i> : a comprehensive review. <i>Memo - Magazine of European Medical Oncology</i> , 2014, 7, 34-38.	0.3	0
168	The evolving classification of soft tissue tumours – an update based on the new 2013 <i>WHO</i> classification. <i>Histopathology</i> , 2014, 64, 2-11.	1.6	393
169	Biochemistry of the tale transcription factors PREP, MEIS, and PBX in vertebrates. <i>Developmental Dynamics</i> , 2014, 243, 59-75.	0.8	125
170	Molecular Testing in Cancer. , 2014, , .		2
171	Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. <i>Nature Reviews Cancer</i> , 2014, 14, 108-119.	12.8	442
172	Novel uses of immunohistochemistry in the diagnosis and classification of soft tissue tumors. <i>Modern Pathology</i> , 2014, 27, S47-S63.	2.9	62
173	Gastrointestinal stromal tumors: what do we know now?. <i>Modern Pathology</i> , 2014, 27, S1-S16.	2.9	140
174	<i>GIST</i> Treatment Options after Tyrosine Kinase Inhibitors. <i>Current Treatment Options in Oncology</i> , 2014, 15, 493-506.	1.3	25

#	ARTICLE	IF	CITATIONS
175	Renal Carcinoma Associated With Succinate Dehydrogenase B Mutation: A New and Unique Subtype of Renal Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, e10-e13.	0.8	31
176	The Clinical Phenotype of <i>SDHC</i> -Associated Hereditary Paraganglioma Syndrome (PGL3). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1482-E1486.	1.8	48
177	<i>SDHAF4</i> Promotes Mitochondrial Succinate Dehydrogenase Activity and Prevents Neurodegeneration. <i>Cell Metabolism</i> , 2014, 20, 241-252.	7.2	88
178	The role of mutation of metabolism-related genes in genomic hypermethylation. <i>Biochemical and Biophysical Research Communications</i> , 2014, 455, 16-23.	1.0	25
179	Oncometabolites-driven tumorigenesis: From genetics to targeted therapy. <i>International Journal of Cancer</i> , 2014, 135, 2237-2248.	2.3	119
180	Defects in mitochondrial metabolism and cancer. <i>Cancer & Metabolism</i> , 2014, 2, 10.	2.4	208
181	Transcription factor <i>PREP1</i> induces EMT and metastasis by controlling the TGF- β -SMAD3 pathway in non-small cell lung adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3775-84.	3.3	87
182	Germline mutations in <i>FH</i> confer predisposition to malignant pheochromocytomas and paragangliomas. <i>Human Molecular Genetics</i> , 2014, 23, 2440-2446.	1.4	316
183	Exploring the association of succinate dehydrogenase complex mutations with lymphoid malignancies. <i>Familial Cancer</i> , 2014, 13, 507-511.	0.9	19
184	Thyroid Hormone Inactivation in Gastrointestinal Stromal Tumors. <i>New England Journal of Medicine</i> , 2014, 371, 84-87.	13.9	19
185	Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1563-1570.	0.8	252
186	Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) – A review. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 53, 514-519.	1.2	125
187	Analysis of all subunits, <i>SDHA</i> , <i>SDHB</i> , <i>SDHC</i> , <i>SDHD</i> , of the succinate dehydrogenase complex in <i>KIT/PDGFR</i> A wild-type GIST. <i>European Journal of Human Genetics</i> , 2014, 22, 32-39.	1.4	90
188	Gastrointestinal Stromal Tumors, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 853-862.	2.3	96
189	Molecular Pathology of Soft-Tissue Neoplasms and Its Role in Clinical Practice. <i>Cancer Control</i> , 2015, 22, 186-192.	0.7	17
190	<i>SDHC</i> methylation in gastrointestinal stromal tumors (GIST): a case report. <i>BMC Medical Genetics</i> , 2015, 16, 87.	2.1	22
191	And the GIST is: When one has a <i>GIST</i> , think of an association!. <i>Cancer</i> , 2015, 121, 2871-2873.	2.0	3
192	An immunohistochemical study of potential diagnostic and therapeutic biomarkers of wild-type gastrointestinal stromal tumours. <i>Histopathology</i> , 2015, 67, 378-385.	1.6	4

#	ARTICLE	IF	CITATIONS
193	Pheochromocytomas and Paragangliomas. <i>Advances in Anatomic Pathology</i> , 2015, 22, 283-293.	2.4	17
194	A Novel SDHA-deficient Renal Cell Carcinoma Revealed by Comprehensive Genomic Profiling. <i>American Journal of Surgical Pathology</i> , 2015, 39, 858-863.	2.1	56
195	Response to correspondence: An immunohistochemical study of potential diagnostic and therapeutic biomarkers of wild-type gastrointestinal stromal tumours. <i>Histopathology</i> , 2015, 67, 747-749.	1.6	0
196	Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis. <i>International Journal of Molecular Sciences</i> , 2015, 16, 15592-15608.	1.8	32
197	Inhibition of KIT-Glycosylation by 2-Deoxyglucose Abrogates KIT-Signaling and Combination with ABT-263 Synergistically Induces Apoptosis in Gastrointestinal Stromal Tumor. <i>PLoS ONE</i> , 2015, 10, e0120531.	1.1	14
198	KIT Mutation and Loss of 14q May Be Sufficient for the Development of Clinically Symptomatic Very Low-Risk GIST. <i>PLoS ONE</i> , 2015, 10, e0130149.	1.1	6
199	Succinate Dehydrogenase Loss in Familial Paraganglioma: Biochemistry, Genetics, and Epigenetics. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-14.	0.6	28
200	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). <i>Modern Pathology</i> , 2015, 28, 807-821.	2.9	176
201	How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models. <i>Mutation Research - Reviews in Mutation Research</i> , 2015, 764, 16-30.	2.4	158
202	An Update on the Application of Newly Described Immunohistochemical Markers in Soft Tissue Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 106-121.	1.2	25
203	Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways. <i>Cancer Medicine</i> , 2015, 4, 101-103.	1.3	80
204	KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation. <i>Journal of Clinical Oncology</i> , 2015, 33, e93-e96.	0.8	48
205	State of the Art in the Treatment of Gastrointestinal Stromal Tumors. <i>Gastrointestinal Tumors</i> , 2014, 1, 221-236.	0.3	2
206	MicroRNAs and Gastrointestinal Stromal Tumor. <i>Advances in Experimental Medicine and Biology</i> , 2015, 889, 51-70.	0.8	1
208	Genotyping and immunohistochemistry of gastrointestinal stromal tumors: An update. <i>Seminars in Diagnostic Pathology</i> , 2015, 32, 392-399.	1.0	39
209	A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. <i>Genetics in Medicine</i> , 2015, 17, 70-87.	1.1	418
210	Hereditary Kidney Cancer Syndromes. , 2015, , 123-133.		0
211	Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. <i>Oncologist</i> , 2015, 20, 823-830.	1.9	26

#	ARTICLE	IF	CITATIONS
212	DNA Methylation and Hydroxymethylation in Cancer. , 2015, , 9-30.		4
213	Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor. Expert Opinion on Investigational Drugs, 2015, 24, 1045-1058.	1.9	1
214	Select Biomarkers for Tumors of the Gastrointestinal Tract: Present and Future. Archives of Pathology and Laboratory Medicine, 2015, 139, 457-468.	1.2	9
215	Classification of <i>KIT/PDGFR</i> wild-type gastrointestinal stromal tumors: implications for therapy. Expert Review of Anticancer Therapy, 2015, 15, 623-628.	1.1	26
216	Impact of age and gender on tumor related prognosis in gastrointestinal stromal tumors (GIST). BMC Cancer, 2015, 15, 57.	1.1	39
218	GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer. Journal of Clinical Oncology, 2015, 33, 1849-1854.	0.8	41
219	Molecular diagnostics in soft tissue sarcomas and gastrointestinal stromal tumors. Journal of Surgical Oncology, 2015, 111, 520-531.	0.8	13
220	Rare childhood cancers—an increasing entity requiring the need for global consensus and collaboration. Cancer Medicine, 2015, 4, 819-824.	1.3	16
221	15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma—paraganglioma syndromes characterized by germline SDHB and SDHD mutations. Endocrine-Related Cancer, 2015, 22, T71-T82.	1.6	52
222	15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1–5. Endocrine-Related Cancer, 2015, 22, T91-T103.	1.6	167
223	Carney triad, SDH-deficient tumors, and <i>Sdhb</i> ^{+/-} mice share abnormal mitochondria. Endocrine-Related Cancer, 2015, 22, 345-352.	1.6	23
224	Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. Genetics in Medicine, 2015, 17, 391-395.	1.1	41
225	Personalized Approaches to Gastrointestinal Cancers. Surgical Clinics of North America, 2015, 95, 1081-1094.	0.5	5
226	Genetics of Gastrointestinal Stromal Tumors. Surgical Pathology Clinics, 2015, 8, 515-524.	0.7	24
227	Soft Tissue Sarcomas. , 2015, , 609-618.e2.		0
228	Research into cancer metabolomics: Towards a clinical metamorphosis. Seminars in Cell and Developmental Biology, 2015, 43, 52-64.	2.3	36
229	Rare Tumors in Children: Progress Through Collaboration. Journal of Clinical Oncology, 2015, 33, 3047-3054.	0.8	36
230	Targeting Disease Persistence in Gastrointestinal Stromal Tumors. Stem Cells Translational Medicine, 2015, 4, 702-707.	1.6	9

#	ARTICLE	IF	CITATIONS
231	Protein-mediated assembly of succinate dehydrogenase and its cofactors. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2015, 50, 168-180.	2.3	87
232	Gastrointestinal stromal tumor: Recent advances in pathology and genetics. <i>Pathology International</i> , 2015, 65, 9-18.	0.6	45
233	Gastrointestinal, Pancreatic and Hepatic Malignancies in Children. , 2015, , 245-269.		0
234	Targeted Therapy of Soft Tissue Sarcoma: There is More than one Way to Skin a Cat!. <i>Chemotherapy</i> , 2016, 05, .	0.0	1
235	Pancreatic GIST in a Patient with Limited Stage Small Cell Lung Cancer: A Case Report and Review of Published Cases. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-6.	0.2	5
236	Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor. <i>Cancer Research and Treatment</i> , 2016, 48, 1155-1166.	1.3	142
237	Familial Papillary Thyroid Carcinoma in a Large Brazilian Family Is Not Associated with Succinate Dehydrogenase Defects. <i>European Thyroid Journal</i> , 2016, 5, 94-99.	1.2	4
238	Dynamic changes in the gene expression profile during rat oral carcinogenesis induced by 4-nitroquinoline 1-oxide. <i>Molecular Medicine Reports</i> , 2016, 13, 2561-2569.	1.1	5
239	Conventional Risk Stratification Fails to Predict Progression of Succinate Dehydrogenase-deficient Gastrointestinal Stromal Tumors. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1616-1621.	2.1	56
240	Role of mitochondrial dysfunction in cancer progression. <i>Experimental Biology and Medicine</i> , 2016, 241, 1281-1295.	1.1	212
241	Long-term outcome of molecular subgroups of gastrointestinal stromal tumour patients treated with standard-dose imatinib in the BFR14 trial: The wild-type gastrointestinal stromal tumours are not a single group yet. <i>European Journal of Cancer</i> , 2016, 58, 38-40.	1.3	0
242	Use of monoclonal antibodies to detect specific mutations in formalin-fixed, paraffin-embedded tissue sections. <i>Human Pathology</i> , 2016, 53, 168-177.	1.1	11
243	A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas. <i>Pituitary</i> , 2016, 19, 407-414.	1.6	12
244	Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults. <i>JAMA Oncology</i> , 2016, 2, 941.	3.4	21
245	Pediatric soft tissue tumor pathology: A happy morpho-molecular union. <i>Seminars in Diagnostic Pathology</i> , 2016, 33, 377-395.	1.0	3
246	Cytologic and Immunohistochemical Evaluation of Low-Grade Spindle Cell Lesions of the Gastrointestinal Tract. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1038-1044.	1.2	12
247	Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. <i>Nature Reviews Cancer</i> , 2016, 16, 680-693.	12.8	306
248	Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors. <i>Modern Pathology</i> , 2016, 29, 1424-1432.	2.9	16

#	ARTICLE	IF	CITATIONS
249	Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma. <i>Surgical Pathology Clinics</i> , 2016, 9, 457-473.	0.7	42
250	Mitochondrial metabolic remodeling in response to genetic and environmental perturbations. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2016, 8, 272-285.	6.6	17
251	Refinements in Sarcoma Classification in the Current 2013 World Health Organization Classification of Tumours of Soft Tissue and Bone. <i>Surgical Oncology Clinics of North America</i> , 2016, 25, 621-643.	0.6	131
252	Management of Gastrointestinal Stromal Tumors. <i>Surgical Clinics of North America</i> , 2016, 96, 1059-1075.	0.5	13
253	“Wild type” GIST: Clinicopathological features and clinical practice. <i>Pathology International</i> , 2016, 66, 431-437.	0.6	61
254	Small Intestinal Cancers. , 2016, , 519-553.		0
255	Management of renal cell carcinoma in young patients and patients with hereditary syndromes. <i>Current Opinion in Urology</i> , 2016, 26, 396-404.	0.9	9
256	Targeting MTHFD2 in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2016, 213, 1285-1306.	4.2	118
257	Gene expression identifies heterogeneity of metastatic behavior among gastrointestinal stromal tumors. <i>Journal of Translational Medicine</i> , 2016, 14, 51.	1.8	3
258	Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches. <i>Oncology and Therapy</i> , 2016, 4, 1-16.	1.0	2
259	Rethinking pheochromocytomas and paragangliomas from a genomic perspective. <i>Oncogene</i> , 2016, 35, 1080-1089.	2.6	50
260	Gastrointestinal Stromal Tumors. , 2016, , 25-36.		1
261	The Emerging Hallmarks of Cancer Metabolism. <i>Cell Metabolism</i> , 2016, 23, 27-47.	7.2	3,943
262	Imatinib-Sensitizing <i>KIT</i> Mutation in a Carney-Stratakis-Associated GI Stromal Tumor. <i>Journal of Clinical Oncology</i> , 2016, 34, e99-e103.	0.8	12
263	Metabolic changes associated with tumor metastasis, part 2: Mitochondria, lipid and amino acid metabolism. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 1349-1363.	2.4	101
265	Molecular Subtypes of <i>KIT/PDGFR</i> Wild-Type Gastrointestinal Stromal Tumors. <i>JAMA Oncology</i> , 2016, 2, 922.	3.4	291
266	SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv287.	3.0	92
267	<i>In Vivo</i> Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of <i>SDHx</i> Mutations in Paraganglioma. <i>Clinical Cancer Research</i> , 2016, 22, 1120-1129.	3.2	54

#	ARTICLE	IF	CITATIONS
268	Carney triad can be (rarely) associated with germline succinate dehydrogenase defects. <i>European Journal of Human Genetics</i> , 2016, 24, 569-573.	1.4	57
269	Alpha-Ketoglutarate as a Molecule with Pleiotropic Activity: Well-Known and Novel Possibilities of Therapeutic Use. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2017, 65, 21-36.	1.0	140
270	Large Epigastric Cystic Lesion in a Pregnant Woman. <i>JAMA Oncology</i> , 2017, 3, 557.	3.4	3
271	Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST. <i>Molecular Cancer Research</i> , 2017, 15, 553-562.	1.5	53
272	Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches. <i>Oncogene</i> , 2017, 36, 3359-3374.	2.6	219
273	Genetic alterations in Krebs cycle and its impact on cancer pathogenesis. <i>Biochimie</i> , 2017, 135, 164-172.	1.3	80
274	Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. <i>Journal of Clinical Oncology</i> , 2017, 35, 523-528.	0.8	58
275	Glutaminolysis: A Hallmark of Cancer Metabolism. <i>Annual Review of Biomedical Engineering</i> , 2017, 19, 163-194.	5.7	528
276	Cancer metabolism in space and time: Beyond the Warburg effect. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2017, 1858, 556-572.	0.5	147
277	GEIS guidelines for gastrointestinal sarcomas (GIST). <i>Cancer Treatment Reviews</i> , 2017, 55, 107-119.	3.4	114
278	Somatic mutational spectrum analysis in a prospective series of 104 gastrointestinal stromal tumors. <i>Oncology Reports</i> , 2017, 37, 1671-1681.	1.2	2
279	The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. <i>Nature Medicine</i> , 2017, 23, 301-313.	15.2	79
280	Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine. <i>EMBO Journal</i> , 2017, 36, 1302-1315.	3.5	424
281	Mitochondrial determinants of cancer health disparities. <i>Seminars in Cancer Biology</i> , 2017, 47, 125-146.	4.3	68
282	Wnt/ β -catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1954-1966.	1.9	41
283	SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1421-1435.	1.2	63
284	Mitochondrial DNA variants in colorectal carcinogenesis: Drivers or passengers?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1905-1914.	1.2	21
288	Hereditary Kidney Cancer Syndromes and Surgical Management of the Small Renal Mass. <i>Urologic Clinics of North America</i> , 2017, 44, 155-167.	0.8	5

#	ARTICLE	IF	CITATIONS
289	Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 445-457.	1.5	34
290	Metabolic synthetic lethality in cancer therapy. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2017, 1858, 723-731.	0.5	50
291	Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib. <i>European Journal of Cancer</i> , 2017, 86, 226-232.	1.3	13
292	The Hereditary Paraganglioma-Pheochromocytoma Syndrome: No Time to Waste. <i>JAMA Oncology</i> , 2017, 3, 1739.	3.4	1
293	The Hereditary Paraganglioma-Pheochromocytoma Syndrome: No Time to Waste—Reply. <i>JAMA Oncology</i> , 2017, 3, 1740.	3.4	0
294	Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy. <i>BioDrugs</i> , 2017, 31, 379-392.	2.2	8
295	Surgical Pathology of Gastrointestinal Stromal Tumors: Practical Implications of Morphologic and Molecular Heterogeneity for Precision Medicine. <i>Advances in Anatomic Pathology</i> , 2017, 24, 336-353.	2.4	29
296	Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance. <i>Clinical Cancer Research</i> , 2017, 23, 6733-6743.	3.2	12
297	Clinicopathologic study of succinate-dehydrogenase-deficient gastrointestinal stromal tumors. <i>Medicine (United States)</i> , 2017, 96, e7668.	0.4	14
298	Mechanism of Resistance in Gastrointestinal Stromal Tumors. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 195-202.	0.9	4
299	The TCA cycle as a bridge between oncometabolism and DNA transactions in cancer. <i>Seminars in Cancer Biology</i> , 2017, 47, 50-56.	4.3	60
300	The progressive fragmentation of the KIT/PDGFR α wild-type (WT) gastrointestinal stromal tumors (GIST). <i>Journal of Translational Medicine</i> , 2017, 15, 113.	1.8	43
301	IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas. <i>Clinical Sarcoma Research</i> , 2017, 7, 8.	2.3	50
302	What is New in Gastrointestinal Stromal Tumor?. <i>Advances in Anatomic Pathology</i> , 2017, 24, 259-267.	2.4	61
303	Succinate dehydrogenase deficiency in a PDGFRA mutated GIST. <i>BMC Cancer</i> , 2017, 17, 512.	1.1	21
304	10 Iron-sulfur proteins and human diseases. , 2017, , 227-306.		0
305	The clinical genetics of pheochromocytoma and paraganglioma. <i>Archives of Endocrinology and Metabolism</i> , 2017, 61, 490-500.	0.3	17
306	Succinate: An initiator in tumorigenesis and progression. <i>Oncotarget</i> , 2017, 8, 53819-53828.	0.8	87

#	ARTICLE	IF	CITATIONS
307	Current research and treatment for gastrointestinal stromal tumors. <i>World Journal of Gastroenterology</i> , 2017, 23, 4856.	1.4	36
308	Therapeutic strategies for wild-type gastrointestinal stromal tumor: is it different from KIT or PDGFRA-mutated GISTs?. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 92-92.	1.5	7
309	How best to manage gastrointestinal stromal tumor. <i>World Journal of Clinical Oncology</i> , 2017, 8, 135.	0.9	19
310	Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 513-523.	0.6	12
311	Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. <i>World Journal of Urology</i> , 2018, 36, 1891-1898.	1.2	105
312	Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 443-458.	12.5	56
313	PREP1 tumor suppressor protects the late-replicating DNA by controlling its replication timing and symmetry. <i>Scientific Reports</i> , 2018, 8, 3198.	1.6	18
315	Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes <i>SDHB</i> , <i>SDHC</i> and <i>SDHD</i> . <i>Journal of Medical Genetics</i> , 2018, 55, 384-394.	1.5	177
316	The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms. <i>Laboratory Investigation</i> , 2018, 98, 414-426.	1.7	22
317	The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 221-229.	1.4	39
318	Survivin is a novel transcription regulator of KIT and is downregulated by miRNA-494 in gastrointestinal stromal tumors. <i>International Journal of Cancer</i> , 2018, 142, 2080-2093.	2.3	21
319	Successful induction therapy with sequential CVD followed by high-dose lanreotide in for metastatic SDHB paraganglioma: Case report. <i>Journal of Clinical and Translational Endocrinology: Case Reports</i> , 2018, 7, 8-13.	0.4	3
320	Gastrointestinal Stromal Tumors: The GIST of Precision Medicine. <i>Trends in Cancer</i> , 2018, 4, 74-91.	3.8	71
321	Succinate dehydrogenase (SDH) deficiency, Carney triad and the epigenome. <i>Molecular and Cellular Endocrinology</i> , 2018, 469, 107-111.	1.6	45
322	Next generation immunohistochemistry: Emerging substitutes to genetic testing?. <i>Seminars in Diagnostic Pathology</i> , 2018, 35, 161-169.	1.0	31
323	The emerging role and targetability of the TCA cycle in cancer metabolism. <i>Protein and Cell</i> , 2018, 9, 216-237.	4.8	345
324	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. , 2018, 181, 49-75.		9
325	Recent advances in the diagnosis of soft tissue tumours. <i>Pathology</i> , 2018, 50, 37-48.	0.3	29

#	ARTICLE	IF	CITATIONS
326	Clinical evaluation and treatment of pheochromocytoma. <i>Annals of Clinical Biochemistry</i> , 2018, 55, 34-48.	0.8	32
327	Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2018, 10, e1406.	6.6	70
328	Metabolic interactions in cancer: cellular metabolism at the interface between the microenvironment, the cancer cell phenotype and the epigenetic landscape. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2018, 10, e1397.	6.6	47
329	DIAGNOSIS of ENDOCRINE DISEASE: SDHx mutations: beyond pheochromocytomas and paragangliomas. <i>European Journal of Endocrinology</i> , 2018, 178, R11-R17.	1.9	22
330	Succinate dehydrogenase (SDH)â€deficient neoplasia. <i>Histopathology</i> , 2018, 72, 106-116.	1.6	181
331	Gain of TP53 Mutation in Imatinib-treated SDH-Deficient Gastrointestinal Stromal Tumor and Clinical Utilization of Targeted Next-generation Sequencing Panel for Therapeutic Decision Support. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 573-578.	0.6	5
332	Contemporary Sarcoma Diagnosis, Genetics, and Genomics. <i>Journal of Clinical Oncology</i> , 2018, 36, 101-110.	0.8	102
333	Translating In Vivo Metabolomic Analysis of Succinate Dehydrogenaseâ€Deficient Tumors Into Clinical Utility. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	22
334	Mechanisms of Drug Resistance in Cancer Therapy. <i>Handbook of Experimental Pharmacology</i> , 2018, , .	0.9	1
335	Asian consensus guidelines for gastrointestinal stromal tumor: what is the same and what is different from global guidelines. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 11-11.	1.5	20
336	Coding and Non-coding: Molecular Portrait of GIST and its Clinical Implication.. <i>Current Molecular Medicine</i> , 2018, 18, 252-259.	0.6	7
337	Mitochondrial DNA Variations in Tumors: Drivers or Passengers?. , 2018, , .		3
338	An update on adrenal endocrinology: significant discoveries in the last 10Âyears and where the field is heading in the next decade. <i>Hormones</i> , 2018, 17, 479-490.	0.9	5
339	Gastrointestinal stromal tumors: A multidisciplinary challenge. <i>World Journal of Gastroenterology</i> , 2018, 24, 1925-1941.	1.4	54
340	Approach to wild-type gastrointestinal stromal tumors. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 92-92.	1.5	19
341	Clinical significance and peculiarities of succinate dehydrogenase B and hypoxia inducible factor 1Î± expression in parasympathetic versus sympathetic paragangliomas. <i>Head and Neck</i> , 2019, 41, 79-91.	0.9	5
342	Gastrointestinal Stromal Tumors (GIST). , 2018, , .		0
343	Hydroxysteroid 11-Beta Dehydrogenase 1 Overexpression with Copy-Number Gain and Missense Mutations in Primary Gastrointestinal Stromal Tumors. <i>Journal of Clinical Medicine</i> , 2018, 7, 408.	1.0	9

#	ARTICLE	IF	CITATIONS
344	Gastrointestinal Stromal Tumors of the Distal Gastrointestinal Tract. <i>Clinics in Colon and Rectal Surgery</i> , 2018, 31, 295-300.	0.5	12
345	Application of ancillary studies in soft tissue cytology using a pattern-based approach. <i>Cancer Cytopathology</i> , 2018, 126, 691-710.	1.4	7
346	A Clinical Roadmap to Investigate the Genetic Basis of Pediatric Pheochromocytoma: Which Genes Should Physicians Think About?. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-14.	0.6	11
347	Epigenetics: an alternative pathway in GISTs tumorigenesis. <i>Neoplasma</i> , 2018, 65, 477-493.	0.7	7
348	Metabolism and Transcription in Cancer: Merging Two Classic Tales. <i>Frontiers in Cell and Developmental Biology</i> , 2017, 5, 119.	1.8	35
349	Pheochromocytoma/Paraganglioma: A Poster Child for Cancer Metabolism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1779-1789.	1.8	5
350	Pathobiological Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes. <i>Cancer Discovery</i> , 2018, 8, 1438-1457.	7.7	38
351	Mesenchymal Tumors of the Gastrointestinal Tract. , 2019, , 459-498.		3
352	Applications of Molecular Testing to Differential Diagnosis. , 2019, , 513-556.		0
353	Epigenome modifiers and metabolic rewiring: New frontiers in therapeutics. , 2019, 193, 178-193.		13
354	Molecular biomarkers for prognosis of gastrointestinal stromal tumor. <i>Clinical and Translational Oncology</i> , 2019, 21, 145-151.	1.2	25
355	Genetic and epigenetic alterations of SDH genes in patients with sporadic succinate dehydrogenase-deficient gastrointestinal stromal tumors. <i>Pathology International</i> , 2019, 69, 350-359.	0.6	4
356	Familial paraganglioma due to a novel SDHB mutation: familial phenotypic heterogeneity and a potentially novel manifestation. <i>International Journal of Endocrine Oncology</i> , 2019, 6, IJE12.	0.4	1
357	Cell Metabolism in Cancer: An Energetic Switch. <i>Learning Materials in Biosciences</i> , 2019, , 97-116.	0.2	0
358	Principles of Local Therapy of Soft Tissue Neoplasms. , 2019, , 55-65.		0
359	Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. <i>Nature</i> , 2019, 575, 229-233.	13.7	164
360	A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2019, 25, 6302-6308.	3.2	13
361	Paragangliomas in Carney-Stratakis Syndrome. <i>Hormone and Metabolic Research</i> , 2019, 51, 437-442.	0.7	5

#	ARTICLE	IF	CITATIONS
362	The Impact Of Succinate Dehydrogenase Gene (SDH) Mutations In Renal Cell Carcinoma (RCC): A Systematic Review. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7929-7940.	1.0	22
363	Practical Application of Cytology and Core Biopsy in the Diagnosis of Mesenchymal Tumors. <i>Surgical Pathology Clinics</i> , 2019, 12, 227-248.	0.7	9
364	Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984975.	1.4	3
365	Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6083-6101.	2.9	17
366	Loss of succinate dehydrogenase B immunohistochemical expression distinguishes pulmonary chondromas from hamartomas. <i>Histopathology</i> , 2019, 75, 825-832.	1.6	6
367	Molecular and Cell Biology of Cancer. <i>Learning Materials in Biosciences</i> , 2019, , .	0.2	3
368	Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. <i>Cancer & Metabolism</i> , 2019, 7, 6.	2.4	51
369	c-KIT mutation in a succinate dehydrogenase-deficient gastric GIST. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 798-803.	1.5	7
370	Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View. <i>Cancers</i> , 2019, 11, 679.	1.7	72
371	GATA1 isoforms differently contribute to the production and compartmentation of reactive oxygen species in the myeloid leukemia cell line K562. <i>Journal of Cellular Physiology</i> , 2019, 234, 20829-20846.	2.0	11
372	The loss of succinate dehydrogenase B expression is frequently identified in hemangioblastoma of the central nervous system. <i>Scientific Reports</i> , 2019, 9, 5873.	1.6	9
373	Engineering Multidimensional Evolutionary Forces to Combat Cancer. <i>Cancer Discovery</i> , 2019, 9, 587-604.	7.7	13
374	Micromanaging aerobic respiration and glycolysis in cancer cells. <i>Molecular Metabolism</i> , 2019, 23, 98-126.	3.0	73
375	Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies. <i>Cancers</i> , 2019, 11, 436.	1.7	33
376	Gastrointestinal stromal tumors – Summary of mutational status of the primary/secondary KIT/PDGFR α mutations, BRAF mutations and SDH defects. <i>Pathology Research and Practice</i> , 2019, 215, 152708.	1.0	20
377	Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 525-535.	2.7	23
378	Targeting the interplay between metabolism and epigenetics in cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 92-99.	1.1	12
379	Primary hepatic gastrointestinal stromal tumor with right adrenal gland invasion. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlo</i>	0.4	8

#	ARTICLE	IF	CITATIONS
380	Complete response to sunitinib for more than three years in a patient with a jejunum gastrointestinal stromal tumor. <i>Medicine (United States)</i> , 2019, 98, e14060.	0.4	2
381	New therapeutic agents in gastrointestinal stromal tumours. <i>Current Opinion in Oncology</i> , 2019, 31, 322-328.	1.1	13
382	Sarcosine is a prostate epigenetic modifier that elicits aberrant methylation patterns through the SAM \rightarrow DNMTs axis. <i>Molecular Oncology</i> , 2019, 13, 1002-1017.	2.1	14
383	Can subunit-specific phenotypes guide surveillance imaging decisions in asymptomatic SDH mutation carriers?. <i>Clinical Endocrinology</i> , 2019, 90, 31-46.	1.2	27
384	Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor With SDHC Germline Mutation and Bilateral Renal and Neck Cysts. <i>Pediatric and Developmental Pathology</i> , 2019, 22, 265-268.	0.5	2
385	Mitochondria as playmakers of apoptosis, autophagy and senescence. <i>Seminars in Cell and Developmental Biology</i> , 2020, 98, 139-153.	2.3	305
386	Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumors. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 655-660.	1.2	47
387	Clinical implications of the oncometabolite succinate in SDH mutation carriers. <i>Clinical Genetics</i> , 2020, 97, 39-53.	1.0	39
388	Metabolic Drivers in Hereditary Cancer Syndromes. <i>Annual Review of Cancer Biology</i> , 2020, 4, 77-97.	2.3	32
389	Mitochondrial Dysfunction at the Center of Cancer Therapy. <i>Antioxidants and Redox Signaling</i> , 2020, 32, 309-330.	2.5	54
390	Imaging in gynecological disease (19): clinical and ultrasound features of extragastrointestinal stromal tumors (GIST). <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 56, 749-758.	0.9	8
391	Pediatric gastrointestinal stromal tumor: Report of two novel patients harboring germline variants in SDHB and SDHC genes. <i>Cancer Genetics</i> , 2020, 241, 61-65.	0.2	4
392	Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. <i>Clinical Cancer Research</i> , 2020, 26, 1837-1845.	3.2	32
393	Non-Coding RNAs, a Novel Paradigm for the Management of Gastrointestinal Stromal Tumors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6975.	1.8	5
394	Effect of Citric Acid Cycle Genetic Variants and Their Interactions with Obesity, Physical Activity and Energy Intake on the Risk of Colorectal Cancer: Results from a Nested Case-Control Study in the UK Biobank. <i>Cancers</i> , 2020, 12, 2939.	1.7	5
395	Abnormal MGMT Promoter Methylation in Gastrointestinal Stromal Tumors: Genetic Susceptibility and Association with Clinical Outcome. <i>Cancer Management and Research</i> , 2020, Volume 12, 9941-9952.	0.9	5
396	A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: Beyond pheochromocytoma and paraganglioma. <i>Clinical Endocrinology</i> , 2020, 93, 528-538.	1.2	36
397	The Significance of Mitochondrial Dysfunction in Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5598.	1.8	141

#	ARTICLE	IF	CITATIONS
398	The epigenomics of sarcoma. <i>Nature Reviews Cancer</i> , 2020, 20, 608-623.	12.8	121
399	Mefloquine Inhibits Esophageal Squamous Cell Carcinoma Tumor Growth by Inducing Mitochondrial Autophagy. <i>Frontiers in Oncology</i> , 2020, 10, 1217.	1.3	12
400	A Comprehensive Proteomics Analysis of the JC Virus (JCV) Large and Small Tumor Antigen Interacting Proteins: Large T Primarily Targets the Host Protein Complexes with V-ATPase and Ubiquitin Ligase Activities While Small t Mostly Associates with Those Having Phosphatase and Chromatin-Remodeling Functions. <i>Viruses</i> , 2020, 12, 1192.	1.5	6
401	SDHx and Non-Chromaffin Tumors: A Mediastinal Germ Cell Tumor Occurring in a Young Man with Germline SDHB Mutation. <i>Medicina (Lithuania)</i> , 2020, 56, 561.	0.8	3
402	Glutamine reliance in cell metabolism. <i>Experimental and Molecular Medicine</i> , 2020, 52, 1496-1516.	3.2	391
403	Succinate Dehydrogenase and Ribonucleic Acid Networks in Cancer and Other Diseases. <i>Cancers</i> , 2020, 12, 3237.	1.7	27
404	Morphological features useful in the differential diagnosis between undifferentiated carcinoma and gastrointestinal stromal tumor. <i>Annals of Diagnostic Pathology</i> , 2020, 46, 151527.	0.6	4
405	Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFR/SDH/RAS-P Wild-Type GIST. <i>Frontiers in Oncology</i> , 2020, 10, 504.	1.3	16
406	Germline <i>SDHB</i> inactivating mutation in gastric spindle cell sarcoma. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 601-608.	1.5	4
407	Prognostic Indicators for Gastrointestinal Stromal Tumors: A Review. <i>Translational Oncology</i> , 2020, 13, 100812.	1.7	54
408	Mucosal Schwann Cell Hamartoma in sigmoid colon – A rare case report and review of literature. <i>Human Pathology: Case Reports</i> , 2020, 19, 200337.	0.2	1
409	Advances in histone demethylase KDM4 as cancer therapeutic targets. <i>FASEB Journal</i> , 2020, 34, 3461-3484.	0.2	81
411	The Use of Molecular Subtypes for Precision Therapy of Recurrent and Metastatic Gastrointestinal Stromal Tumor. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 2433-2447.	1.0	10
412	Mitochondrial complex II and reactive oxygen species in disease and therapy. <i>Redox Report</i> , 2020, 25, 26-32.	1.4	85
413	Novel selective hexokinase 2 inhibitor Benitrobenrazide blocks cancer cells growth by targeting glycolysis. <i>Pharmacological Research</i> , 2021, 164, 105367.	3.1	49
414	Comprehensive targeted next-generation sequencing approach in the molecular diagnosis of gastrointestinal stromal tumor. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 239-249.	1.5	28
416	Epigenetic regulations in gastrointestinal: Implications on sensitivity to ionizing radiation, inflammatory diseases, and cancer development. , 2021, , 199-235.		0
418	Cancer metabolism and intervention therapy. <i>Molecular Biomedicine</i> , 2021, 2, 5.	1.7	20

#	ARTICLE	IF	CITATIONS
419	A case of planar-type gastrointestinal stromal tumor of the transverse colon with perforation. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1157-1162.	0.4	0
420	Gene Expression Landscape of SDH-Deficient Gastrointestinal Stromal Tumors. <i>Journal of Clinical Medicine</i> , 2021, 10, 1057.	1.0	9
421	Gastrointestinal stromal tumours. <i>Nature Reviews Disease Primers</i> , 2021, 7, 22.	18.1	169
422	18F-FDG PET/CT Monitoring of Tumor Response to Tyrosine Kinase Inhibitors and Alkylating Drugs in an SDH-Deficient GIST. <i>Clinical Nuclear Medicine</i> , 2021, 46, e515-e517.	0.7	0
423	Genetics of pheochromocytoma and paraganglioma. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 283-290.	1.2	22
424	Familial wild-type gastrointestinal stromal tumour in association with germline truncating variants in both SDHA and PALB2. <i>European Journal of Human Genetics</i> , 2021, 29, 1139-1145.	1.4	1
425	Genome-wide CRISPRi screening identifies OCIAD1 as a prohibitin client and regulatory determinant of mitochondrial Complex III assembly in human cells. <i>ELife</i> , 2021, 10, .	2.8	20
426	Mitochondrial DNA variation and cancer. <i>Nature Reviews Cancer</i> , 2021, 21, 431-445.	12.8	98
427	Carney Triad, Carney-Stratakis Syndrome, 3PAS and Other Tumors Due to SDH Deficiency. <i>Frontiers in Endocrinology</i> , 2021, 12, 680609.	1.5	11
428	Recent Progress and Challenges in the Diagnosis and Treatment of Gastrointestinal Stromal Tumors. <i>Cancers</i> , 2021, 13, 3158.	1.7	33
429	Clinicopathological Features and Outcomes of Gastrointestinal Stromal Tumours in Oman. <i>Sultan Qaboos University Medical Journal</i> , 2021, 21, e237-243.	0.3	0
430	Curative intent treatment of late presented extragastrointestinal stromal tumor: two identical case reports with literature review. <i>Journal of Surgical Case Reports</i> , 2021, 2021, rjab220.	0.2	3
431	Gastrointestinal stromal tumors with <i>BRAF</i> gene fusions. A report of two cases showing low or absent <i>KIT</i> expression resulting in diagnostic pitfalls. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 789-795.	1.5	11
432	Metabolic reprogramming in renal cancer: Events of a metabolic disease. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188559.	3.3	57
433	Tackling Dysfunction of Mitochondrial Bioenergetics in the Brain. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8325.	1.8	5
434	Control of topoisomerase II activity and chemotherapeutic inhibition by TCA cycle metabolites. <i>Cell Chemical Biology</i> , 2022, 29, 476-489.e6.	2.5	10
435	Clinicopathological value of long non-coding RNA profiles in gastrointestinal stromal tumor. <i>PeerJ</i> , 2021, 9, e11946.	0.9	5
436	A proposed risk assessment score for gastrointestinal stromal tumors based on evaluation of 19,030 cases from the National Cancer Database. <i>Journal of Gastroenterology</i> , 2021, 56, 964-975.	2.3	3

#	ARTICLE	IF	CITATIONS
437	Mechanisms Governing Metabolic Heterogeneity in Breast Cancer and Other Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 700629.	1.3	17
438	Mitochondrial Structure and Bioenergetics in Normal and Disease Conditions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 586.	1.8	72
439	The 3PAs syndrome and succinate dehydrogenase deficiency in pituitary tumors. , 2021, , 127-155.		0
440	Targeted Therapy in Gastrointestinal Stromal Tumors. <i>Current Clinical Pathology</i> , 2015, , 163-196.	0.0	1
441	Gastrointestinal Stromal Tumour (GIST): Diagnosis and Treatment. , 2015, , 691-717.		1
442	Gastrointestinal Stromal Tumors. , 2016, , 77-104.		1
444	Gastrointestinal stromal tumours: origin and molecular oncology. , 0, .		1
445	Recent developments in gastroesophageal mesenchymal tumours. <i>Histopathology</i> , 2021, 78, 171-186.	1.6	9
446	Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 3682-3691.	3.9	59
447	Connecting Molecular Pathways to Hereditary Cancer Risk Syndromes. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 81-90.	1.8	19
448	Recent advances in managing gastrointestinal stromal tumor. <i>F1000Research</i> , 2017, 6, 1689.	0.8	8
449	Recent advances in the management of gastrointestinal stromal tumor. <i>World Journal of Clinical Cases</i> , 2020, 8, 3142-3155.	0.3	32
450	Reduced Expression of Fumarate Hydratase in Clear Cell Renal Cancer Mediates HIF-2 α Accumulation and Promotes Migration and Invasion. <i>PLoS ONE</i> , 2011, 6, e21037.	1.1	45
451	Myb-Binding Protein 1A (MYBBP1A) Is Essential for Early Embryonic Development, Controls Cell Cycle and Mitosis, and Acts as a Tumor Suppressor. <i>PLoS ONE</i> , 2012, 7, e39723.	1.1	43
452	ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor. <i>PLoS ONE</i> , 2013, 8, e54477.	1.1	17
453	SMALL BOWEL GIST: CASE REPORTS AND REVIEW OF LITERATURE. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2014, 3, 11601-11607.	0.1	1
454	Gastrointestinal stromal tumour: From the clinic to the molecules. <i>Journal of Cancer Research & Therapy</i> , 2014, 2, 54-67.	0.1	1
455	Genetics of Pheochromocytoma and Paraganglioma. , 0, , 1-22.		5

#	ARTICLE	IF	CITATIONS
456	The Emerging Role of Succinate Dehydrogenase Genes (SDHx) in Tumorigenesis. International Journal of Hematology-Oncology and Stem Cell Research, 0, , .	0.3	9
457	Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients. Oncotarget, 2018, 9, 17576-17588.	0.8	1
458	Integrated genomic analyses identify frequent gene fusion events and <i>VHL</i> inactivation in gastrointestinal stromal tumors. Oncotarget, 2016, 7, 6538-6551.	0.8	29
459	Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 281-293.	0.7	117
460	LASS5 Interacts with SDHB and Synergistically Represses p53 and p21 Activity. Current Molecular Medicine, 2016, 16, 582-590.	0.6	7
461	Mutational Testing in Gastrointestinal Stromal Tumor. Current Cancer Drug Targets, 2019, 19, 688-697.	0.8	6
462	Biomarkers and Novel Therapeutic Targets in Gastrointestinal Stromal Tumors (GISTs). Recent Patents on Anti-Cancer Drug Discovery, 2013, 8, 288-297.	0.8	8
463	Succinate dehydrogenase-deficient gastrointestinal stromal tumors. World Journal of Gastroenterology, 2015, 21, 2303.	1.4	36
464	Rarity among benign gastric tumors: Plexiform fibromyxoma - Report of two cases. World Journal of Gastroenterology, 2017, 23, 5817.	1.4	19
465	Role of succinate dehydrogenase deficiency and oncometabolites in gastrointestinal stromal tumors. World Journal of Gastroenterology, 2020, 26, 5074-5089.	1.4	15
466	Diagnosis and Treatment of Gastrointestinal Stromal Tumor. Korean Journal of Medicine, 2013, 85, 341.	0.1	4
467	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1278-1285.	2.3	185
468	Gastrointestinal Stromal Tumors: Clinicopathology and Advances in Molecular Pathogenesis. North American Journal of Medicine & Science, 2012, 5, 94.	3.8	1
470	Treating Rare Cancer in Children: The Importance of Evidence. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 586-588.	1.8	0
471	Gastrointestinal Stromal Tumors (GISTs). , 2013, , 67-91.		0
472	Applications of Molecular Testing to Differential Diagnosis. , 2013, , 487-523.		0
473	Traitement personnalis�© selon les mutations. , 2013, , 333-345.		0
474	Mesenchymal Tumors of the Gastrointestinal Tract. , 2013, , 437-473.		2

#	ARTICLE	IF	CITATIONS
475	Familial and Hereditary Syndromes. , 2013, , 39-50.		0
477	Molecular Pathology of Bone and Soft Tissue Neoplasms and Potential Targets for Novel Therapy. , 2014, , 397-421.		0
478	Molecular Pathology of Gastrointestinal Tumors. , 2014, , 189-209.		0
479	Therapeutic targets in gastrointestinal stromal tumors. World Journal of Translational Medicine, 2015, 4, 25.	3.5	1
480	Gastrointestinal Stromal Tumors (GIST)â€™Paving the Way for Modern Oncologyâ€™Epidemiology, Diagnosis, Treatment. European Oncology and Haematology, 2015, 11, 57.	0.0	0
481	Pheochromocytoma/Paraganglioma. , 2016, , 8-154-8-159.		0
482	Pathologic Features of Miscellaneous Foregut Malignancies. Cancer Treatment and Research, 2016, 168, 45-58.	0.2	0
483	Gastrointestinal Malignancy: Genetic Implications to Clinical Applications. Cancer Treatment and Research, 2016, 168, 393-479.	0.2	0
484	Inherited GIST. , 2017, , 45-57.		0
485	Surgical treatment for gastrointestinal stromal tumors in children. Onkologiya Zhurnal Imeni P A Gertsena, 2017, 6, 38.	0.0	0
486	Carney Complex. , 2018, , 692-699.		0
487	Pheochromocytoma/Paraganglioma. , 2018, , 462-471.		0
488	Gastrointestinal Cancers in Children. , 2019, , 311-327.		1
489	Gastrointestinal Stromal Tumors. , 2019, , 289-309.		0
490	Gastrointestinal Stromal Tumor (GIST): Diagnosis and Treatment. , 2019, , 817-849.		0
494	Intermediate Malignant and Malignant Tumors of Soft Tissue Featuring a Spindle Cell Morphology. , 2019, , 71-218.		0
495	Metabolic Changes and Their Characterization. , 2020, , 35-70.		1
496	Rare Peritoneal Tumours: Histopathological Diagnosis and Patterns of Peritoneal Dissemination. , 2020, , 181-228.		0

#	ARTICLE	IF	CITATIONS
497	Grossing and reporting of a soft tissue tumor specimen in surgical pathology: Rationale, current evidence, and recommendations. <i>Indian Journal of Cancer</i> , 2020, 58, 17-27.	0.2	1
498	Dissecting the Role of Circular RNAs in Sarcomas with Emphasis on Osteosarcomas. <i>Biomedicines</i> , 2021, 9, 1642.	1.4	4
499	Molecular Pathogenesis of Gastrointestinal Stromal Tumor: A Paradigm for Personalized Medicine. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2022, 17, 323-344.	9.6	8
500	Presence of PDGFRA and DOG1 mutations in gastrointestinal stromal tumors among Chinese population. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 5721-6.	0.5	4
501	A novel germline mutation in SDHA identified in a rare case of gastrointestinal stromal tumor complicated with renal cell carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 12188-97.	0.5	23
503	The Emerging Role of Succinate Dehydrogenase Genes (SDHx) in Tumorigenesis. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 2019, 13, 72-82.	0.3	5
504	Oncometabolites as Regulators of DNA Damage Response and Repair. <i>Seminars in Radiation Oncology</i> , 2022, 32, 82-94.	1.0	3
505	SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor. <i>Frontiers in Oncology</i> , 2021, 11, 778461.	1.3	4
506	Juvenile Gastric Gastrointestinal Stromal Tumor with Lymph Node Metastasis: A Case Report. <i>Japanese Journal of Gastroenterological Surgery</i> , 2022, 55, 25-32.	0.0	0
507	Fundamentals of cell metabolism and cancer. , 2022, , 117-132.		0
508	Role of succinate dehydrogenase in hepatocellular carcinoma. , 2022, , 167-180.		0
509	New treatment strategies for advanced-stage gastrointestinal stromal tumours. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 328-341.	12.5	43
510	Imatinib-associated skin rash is related to treatment outcome in patients with unresectable and/or metastatic gastrointestinal stromal tumor. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 117-125.	0.6	1
512	Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes. <i>Endocrine Pathology</i> , 2022, 33, 197-227.	5.2	24
513	The epigeneticâ€“metabolic interplay in gliomagenesis. <i>Open Biology</i> , 2022, 12, 210350.	1.5	2
514	Mitochondrial complex IV defects induce metabolic and signaling perturbations that expose potential vulnerabilities in HCT116 cells. <i>FEBS Open Bio</i> , 2022, 12, 959-982.	1.0	2
515	Model systems in SDHx-related pheochromocytoma/paraganglioma. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 1177-1201.	2.7	7
516	Mesenchymal neoplasms with NTRK and other kinase gene alterations. <i>Histopathology</i> , 2022, 80, 4-18.	1.6	22

#	ARTICLE	IF	CITATIONS
517	The stomach. , 0, , 1853-1924.		0
525	The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 885-899.	1.8	21
526	Molecular heterogeneity and analysis of the long-term survival of patients with gastrointestinal stromal tumors. Uspehi Molekularnoj Onkologii, 2022, 9, 43-57.	0.1	1
527	Tensin2 Is a Novel Diagnostic Marker in GIST, Associated with Gastric Location and Non-Metastatic Tumors. Cancers, 2022, 14, 3212.	1.7	4
528	Correlation of treatment outcome in sanger/RTâ€qPCR <i>KIT/PDGFR</i> wildâ€type metastatic gastrointestinal stromal tumors with nextâ€generation sequencing results: A singleâ€center report. Oncology Reports, 2022, 48, .	1.2	4
529	Dataset for reporting of gastrointestinal stromal tumours: recommendations from the International Collaboration on Cancer Reporting (<scp>ICCR</scp>). Histopathology, 0, , .	1.6	1
530	A Gastroenterologistâ€™s Approach to the Diagnosis and Management of Gastrointestinal Stromal Tumors. Gastroenterology Clinics of North America, 2022, 51, 609-624.	1.0	4
531	Lymph Node Metastases in Gastrointestinal Stromal Tumors: an Uncommon Event. Annals of Surgical Oncology, 2022, 29, 8641-8648.	0.7	5
532	ASO Author Reflections: Nodal Disease Burden in Patients with Gastrointestinal Stromal Tumor. Annals of Surgical Oncology, 0, , .	0.7	1
533	A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma. Clinical Cancer Research, 2023, 29, 341-348.	3.2	2
534	Current Molecular Profile of Gastrointestinal Stromal Tumors and Systemic Therapeutic Implications. Cancers, 2022, 14, 5330.	1.7	11
535	NCCN Guidelinesâ€™ Insights: Gastrointestinal Stromal Tumors, Version 2.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 1204-1214.	2.3	19
536	Virtual Screening and Biological Activity Evaluation of New Potent Inhibitors Targeting Hexokinase-II. Molecules, 2022, 27, 7555.	1.7	4
537	Cancer-derived extracellular succinate: a driver of cancer metastasis. Journal of Biomedical Science, 2022, 29, .	2.6	16
539	Metabolic determinants of tumour initiation. Nature Reviews Endocrinology, 2023, 19, 134-150.	4.3	16
540	Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations. Npj Precision Oncology, 2023, 7, .	2.3	9
541	Gastrointestinal Stromal Tumor Recurrence Presenting as a Small Bowel Obstruction: A Case Report. Cureus, 2023, , .	0.2	1
543	Insights into the medical management of gastrointestinal stromal tumours: lessons learnt from a dedicated gastrointestinal stromal tumour clinic in North India. Ecancermedalscience, 0, 17, .	0.6	1

#	ARTICLE	IF	CITATIONS
544	TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors. <i>Drugs</i> , 2023, 83, 55-73.	4.9	4
545	The Recent Advances in Molecular Diagnosis of Soft Tissue Tumors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5934.	1.8	1
546	Putative adverse outcome pathways of the male reproductive toxicity derived from toxicological studies of perfluoroalkyl acids. <i>Science of the Total Environment</i> , 2023, 873, 162439.	3.9	3
547	Molecular Mechanisms of Gastrointestinal Stromal Tumors and Their Impact on Systemic Therapy Decision. <i>Cancers</i> , 2023, 15, 1498.	1.7	4
548	SDHA Germline Mutations in SDH-Deficient GISTs: A Current Update. <i>Genes</i> , 2023, 14, 646.	1.0	2
549	Metabolomics in paraganglioma: applications and perspectives from genetics to therapy. <i>Endocrine-Related Cancer</i> , 2023, 30, .	1.6	3
550	Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6026.	1.8	1
551	Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives. <i>Cancers</i> , 2023, 15, 2074.	1.7	1
554	Methylation and hydroxymethylation in cancer. , 2023, , 11-37.		0
566	Gastrointestinal stromal tumor (GIST). , 2016, , 474-490.		0
567	Case Report: Multiple gastrointestinal stromal tumors along with numerous cutaneous neurofibromas: a case description and literature analysis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
571	Case report: A safeguard in the sea of variants of uncertain significance: a case study on child with high risk neuroblastoma and acute myeloid leukemia. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0